Biodegradable Cationic Lipids for Lower-Toxicity Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current siRNA and miRNA constructs face challenges such as susceptibility to nuclease digestion in plasma and limited intracellular delivery when administered systemically, necessitating improved cationic lipids and lipid nanoparticles for protection and efficient delivery.
Innovation Solution
Development of cationic lipids with biodegradable groups incorporated into lipid particles to enhance stability, protect nucleic acids from degradation, and facilitate intracellular delivery, while ensuring rapid metabolism and reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cationic lipids are used to form lipid nanoparticles for nucleic acid delivery, then intracellular delivery and protection from nuclease digestion are improved, but toxicity increases and metabolism is slowed
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by incorporating biodegradable groups (such as ester bonds, amide bonds, or disulfide bonds) into the lipid molecule. These structural parameter changes enable the lipids to be metabolized by cellular enzymes after delivering their cargo, thereby reducing long-term toxicity while maintaining effective protection during delivery
Solution Approach 2:
The biodegradable cationic lipids are designed to fulfill their protective and delivery function temporarily, then degrade into harmless metabolites that can be eliminated by the body. This disposable approach allows the lipid to provide necessary protection from nucleases during transit, but then self-destruct to avoid chronic toxicity accumulation
2Reliability
If cationic lipids are used to form lipid nanoparticles for nucleic acid delivery, then intracellular delivery is improved, but metabolism and removal from the body are slowed
Solution Approach 1:
The patent introduces biodegradable chemical groups into the cationic lipid structure, changing its metabolic parameters. These groups contain cleavable bonds (ester, amide, disulfide) that are stable during delivery but can be hydrolyzed or reduced by cellular enzymes, enabling controlled breakdown and elimination after the delivery function is completed
Solution Approach 2:
The lipid nanoparticle system transitions from a stable, protective state during circulation to a dynamic, degradable state after cellular uptake. The biodegradable groups remain intact during delivery to maintain structural integrity, then become dynamically active when encountered with cellular enzymes, allowing the lipid to self-digest and be removed from the body
3Productivity
If high drug:lipid ratios are achieved in lipid nanoparticles, then delivery efficiency is improved, but stability and protection of nucleic acid may be compromised
Solution Approach 1:
The patent employs composite lipid formulations containing biodegradable cationic lipids combined with neutral lipids, cholesterol, and PEGylated lipids. This composite structure allows the cationic component to provide high drug:lipid ratio binding for efficient delivery, while the other components contribute to overall nanoparticle stability, steric protection, and controlled degradation, achieving a balance between efficiency and stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biodegradable cationic lipids provide high drug:lipid ratios, protect nucleic acids from degradation, enable systemic delivery, and ensure lower toxicity, facilitating effective intracellular delivery of therapeutic agents.
Implementation Method 1
The incorporation of the biodegradable group(s) into the lipid results in faster metabolism and removal of the lipid from the body following delivery of the active agent to a target area
Data Source
AI summary
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.